SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:gup.ub.gu.se/53347"
 

Sökning: onr:"swepub:oai:gup.ub.gu.se/53347" > Oral tolerization w...

Oral tolerization with peptide 336-351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet's disease.

Stanford, M. (författare)
Whittall, T (författare)
Bergmeier, L A (författare)
visa fler...
Lindblad, Marianne, 1941 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för medicinsk mikrobiologi och immunologi,Institute of Medical Microbiology/Immunology
Lundin, Samuel B, 1970 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för medicinsk mikrobiologi och immunologi,Institute of Medical Microbiology/Immunology
Shinnick, T (författare)
Mizushima, Y (författare)
Holmgren, Jan, 1944 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för medicinsk mikrobiologi och immunologi,Institute of Medical Microbiology/Immunology
Lehner, T. (författare)
visa färre...
 (creator_code:org_t)
2004-06-10
2004
Engelska.
Ingår i: Clinical and experimental immunology. - : Oxford University Press (OUP). - 0009-9104 .- 1365-2249. ; 137:1, s. 201-8
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Behcet's disease (BD) specific peptide (p336-351) was identified within the human 60 kD heat shock protein (HSP60). Oral p336-351 induced uveitis in rats which was prevented by oral tolerization with the peptide linked to recombinant cholera toxin B subunit (CTB). This strategy was adopted in a phase I/II clinical trial by oral administration of p336-351-CTB, 3 times weekly, followed by gradual withdrawal of all immunosuppressive drugs used to control the disease in 8 patients with BD. The patients were monitored by clinical and ophthalmological examination, as well as extensive immunological investigations. Oral administration of p336-351-CTB had no adverse effect and withdrawal of the immunosuppressive drugs showed no relapse of uveitis in 5 of 8 patients or 5 of 6 selected patients who were free of disease activity prior to initiating the tolerization regimen. After tolerization was discontinued, 3 of 5 patients remained free of relapsing uveitis for 10-18 months after cessation of all treatment. Control of uveitis and extra-ocular manifestations of BD was associated with a lack of peptide-specific CD4+ T cell proliferation, a decrease in expression of TH1 type cells (CCR5, CXCR3), IFN-gamma and TNF-alpha production, CCR7+ T cells and costimulatory molecules (CD40 and CD28), as compared with an increase in these parameters in patients in whom uveitis had relapsed. The efficacy of oral peptide-CTB tolerization will need to be confirmed in a phase III trial, but this novel strategy in humans might be applicable generally to autoimmune diseases in which specific antigens have been identified.

Nyckelord

Adjuvants
Immunologic
administration & dosage
Administration
Oral
Adult
Antigens
CD
immunology
Behcet Syndrome
complications
immunology
CD4-Positive T-Lymphocytes
Cell Division
immunology
Cholera Toxin
administration & dosage
Humans
Immune Tolerance
Interferon Type II
immunology
Male
Middle Aged
Peptide Fragments
Phenotype
Receptors
Chemokine
immunology
T-Lymphocytes
immunology
Th1 Cells
immunology
Tumor Necrosis Factor-alpha
immunology
Uveitis
complications
immunology
prevention & control

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy